Oncotarget

Research Papers:

Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer

Joost H. van Ginkel, Wendy W.J. de Leng, Remco de Bree, Robert J.J. van Es and Stefan M. Willems _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:61575-61586. https://doi.org/10.18632/oncotarget.11196

Metrics: PDF 1726 views  |   HTML 5065 views  |   ?  


Abstract

Joost H. van Ginkel1,2, Wendy W.J. de Leng2, Remco de Bree3, Robert J.J. van Es1,3, Stefan M. Willems2

1Department of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, The Netherlands

2Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

3Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Correspondence to:

Stefan M. Willems, email: [email protected]

Keywords: head and neck cancer, mutations, next-generation sequencing, TP53, diagnostic biomarkers

Received: May 20, 2016     Accepted: July 28, 2016     Published: August 11, 2016

ABSTRACT

Head and neck squamous cell carcinomas (HNSCC) form a large heterogeneous group of tumors and have a relatively poor outcome in advanced cases. Revealing the underlying genetic mutations in HNSCC facilitates the development of diagnostic biomarkers, which might lead to improved diagnosis and post treatment surveillance. We retrospectively analyzed mutational hotspots using targeted next-generation sequencing (NGS) of 239 HNSCC tumor samples in order to examine the mutational profile of HNSCC. Furthermore, we assessed prevalence, co-occurrence, and synonymy of gene mutations in (matched) tumor samples. TP53 was found mutated the most frequent with mutation rates of up to 83% in all tumors, compared to mutation rates of between 0 and 21% of CDKN2A, PIK3CA, HRAS, CDK4, FBXW7 and RB1. Mutational co-occurrence predominantly existed between TP53 and PIK3CA, TP53 and CDKN2A, and HRAS and PIK3CA. Mutational synonymy between primary tumor and associated metastasis and recurrence was present in respectively 88% and 89%. TP53 mutations were concordantly mutated in 95% of metastases and in 91% of recurrences. This indicates TP53 mutations to be highly prevalent and concordant in primary tumors and associated locoregional metastases and recurrences. In turn, this provides ground for further investigating the use of TP53 mutations as diagnostic biomarkers in HNSCC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11196